Brukinsa shows a more favorable safety profile than Imbruvica, with fewer severe side effects, especially neutropenia. Brukinsa may be preferable for patients at higher infection risk or requiring ...

Progression-free survival and overall response rates greatly improved in patients with CLL/SLL treated with Brukinsa compared with Imbruvica. The risk for disease progression or death was reduced by ...

A committee of the European Medicines Agency (EMA) said that Johnson & Johnson (NYSE:JNJ) withdrew its application seeking expanded approval of blood cancer drug Imbruvica on Dec. 13, 2022. The EMA's ...

Brukinsa (zanubrutinib) is a brand-name oral capsule prescribed to treat certain blood cancers in adults. As with other drugs, Brukinsa can cause side effects. Mild side effects of Brukinsa include ...

Dazzling trial data, followed by FDA approval three months ago in the most common form of leukemia have set BeiGene’s Brukinsa up to become the dominant force in treating blood cancer. AbbVie and ...